ArticleJournal of immunology research2026
Comparative Analysis of Tumor-Immune Microenvironment Diversity Among Biopsy, Resection, and Metastatic Colorectal Cancer Specimens.
Article in Journal of immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative Analysis of Tumor-Immune Microenvironment Diversity Among Biopsy, Resection, and Metastatic Colorectal Cancer Specimens.Journal of immunology research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) tumor immune microenvironment (TIME) components such as programmed death-ligand 1 (PD-L1) and CD4+T/CD8+T cells play an important role in immunotherapy, which is closely related to the treatment and prognosis of patients. Due to the fact that CRC is relatively insidious and most of it has advanced and metastasis when discovered, it is important to use biopsy specimens to accurately assess the TIME before treatment. However, there are no studies investigating the association of TIME in biopsy and excision specimens and in metastatic colorectal lesions.
methodsThis study compares PD-L1 expression and CD4+T and CD8+T cell infiltration as representative indicators of CRC TIME among endoscopic biopsy specimens (n = 20), surgical resection specimens (n = 20), metastasis specimens (n = 29), microsatellite instability (MSI) specimens (n = 15), and microsatellite stable (MSS) specimens (n = 78).
results(1) There was a positive correlation of PD-L1 in tumor cells (TCs) from biopsy and resection (p < 0.05) but not in interstitial cells (ICs) (p > 0.05). CD4+T and CD8+T cells were positively correlated in biopsy and resection specimens (p < 0.05). (2) There are no significant differences in PD-L1-positive cells and CD4+T/CD8+T cell infiltrations between primary lesions of nonmetastatic patients and primary lesions of metastatic patients. (3) Compared with MSS CRC, MSI CRC had higher PD-L1 expression, CD4+T/CD8+T cells, and Ki67-positive rates (p < 0.05).
conclusionCD4+T/CD8+T cell infiltration and PD-L1 expression in resected specimens can be used to predict the progression and growth environment of patients' tumors to a certain extent, which is convenient for clinicians to predict treatment and medication in advance. Metastatic CRC has significant differences in tumor infiltration and MSI from nonmetastatic CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.